Research programme: interleukin 1 beta inhibitors - Opsona

Drug Profile

Research programme: interleukin 1 beta inhibitors - Opsona

Alternative Names: IL1-ß inhibitor - Opsona

Latest Information Update: 03 Feb 2017

Price : $50

At a glance

  • Originator Opsona Therapeutics
  • Class Small molecules
  • Mechanism of Action Interleukin 1 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Inflammation

Highest Development Phases

  • Research Inflammation

Most Recent Events

  • 03 Feb 2017 The interleukin 1 beta inhibitor research programme is still under early research for Inflammation in Ireland (Opsona Therapeutics pipeline, February 2017)
  • 03 Feb 2017 Research programme: interleukin 1 beta inhibitors - Opsona is available for licensing/partnering as of 03 Feb 2017. http://www.opsona.com/Inflammasome
  • 16 Jul 2016 No recent reports of development identified for research development in Inflammation in Ireland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top